Attached files

file filename
8-K - FORM 8-K - BioMed Realty Trust Inca58574e8vk.htm
EX-99.1 - EX-99.1 - BioMed Realty Trust Inca58574exv99w1.htm
Exhibit 99.2
(BIOMED REALTY TRUST, INC.)
SUPPLEMENTAL OPERATING AND FINANCIAL DATA
DECEMBER 31, 2010
         
BioMed Realty Trust, Inc.
  Corporate Communications Contact   www.biomedrealty.com
17190 Bernardo Center Drive
  Rick Howe   (858) 485-9840 phone
San Diego, CA 92128
  Director, Corporate Communications   (858) 485-9843 fax
 
  richard.howe@biomedrealty.com    

 


 

(BIOMED REALTY TRUST, INC.)
TABLE OF CONTENTS
DECEMBER 31, 2010
         
    Page  
Fourth Quarter Highlights
    3  
Investor Information
    4  
Equity Research Coverage
    5  
Financial and Operating Highlights
    6  
Capitalization Summary
    7  
Portfolio Summary
    8  
Consolidated Balance Sheets
    9  
Consolidated Statements of Income
    10  
FFO
    11  
AFFO
    12  
Reconciliation of EBITDA
    13  
Reconciliation of Net Operating Income
    14  
Interest Expense
    15  
Coverage Ratios
    16  
Debt Summary
    17  
Debt Analysis
    18  
Debt Maturities
    19  
Common and Preferred Stock Data
    20  
Market Summary
    21  
Property Listing — Consolidated Portfolio
    22-23  
Development / Redevelopment / Pre-Development / Development Potential
    24  
Property Listing — Unconsolidated Partnerships
    25  
Lease Expirations
    26  
Expirations by Market
    27  
10 Largest Tenants
    28  
Same Property Analysis
    29  
Acquisitions
    30  
Leasing Activity
    31  
Tenant Improvements and Leasing Commissions
    32  
Non-GAAP Financial Measure Definitions
    33  
Property Definitions
    34  
This Supplemental Operating and Financial Data package contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although we believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, you should exercise caution in interpreting and relying on these statements as they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company’s control and could materially affect actual results, performance or achievements. These factors include, without limitation, general risks affecting the real estate industry, the ability to enter into new leases or renew leases on favorable terms, dependence on tenants’ financial condition, competition from other developers, owners and operators of real estate, adverse economic or real estate developments in the life science industry or the company’s target markets, the uncertainty of real estate development, construction and acquisition activity, the ability to complete or integrate acquisitions and developments successfully, reductions in asset valuations and related impairment charges, the availability and terms of financing and the use of debt to fund acquisitions and developments, the ability to refinance indebtedness as it comes due, failure to maintain the company’s investment grade credit ratings with the rating agencies, downturns in the national and local economies, increases in interest rates and volatility in securities markets, potential liability for uninsured losses and environmental contamination, the company’s dependence on key personnel whose continued service is not guaranteed, regulatory and tax law changes and other risks and uncertainties detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
All dollar amounts shown in this report are unaudited.
This Supplemental Operating and Financial Data package is not an offer to sell or solicitation to buy securities of BioMed Realty Trust, Inc. Any offers to sell or solicitations to buy securities of BioMed Realty Trust, Inc. shall be made only by means of a prospectus approved for that purpose.

2


 

(BIOMED REALTY TRUST, INC.)
FOURTH QUARTER HIGHLIGHTS
DECEMBER 31, 2010
  Generated record total revenues for the fourth quarter of $105.0 million, up 19.1% from $88.2 million in the same period in 2009.
    Increased rental revenues for the quarter by 17.6% to a record $79.2 million from $67.3 million in the same period in 2009.
  Reported funds from operations (FFO) for the quarter of $43.6 million, or $0.30 per diluted share, as compared to FFO of $28.0 million, or $0.28 per share in the fourth quarter of 2009, an increase of 7.1%.
 
  Increased adjusted funds from operations (AFFO) per diluted share by 16.7% to $0.28 as compared to $0.24 for the same period in 2009.
 
  Increased same property net operating income (NOI) for the quarter by 6.0% and same property NOI on a cash basis for the quarter by 13.1% as compared to the same period in 2009.
 
  Increased net income to $8.5 million, or $0.06 per diluted share, for the quarter, as compared to $477,000, or $0.00 per diluted share, for the same period in 2009.
 
  Executed 13 leasing transactions representing approximately 329,000 square feet:
    Eight new leases totaling approximately 162,000 square feet.
 
    Five leases amended to extend their terms, totaling approximately 167,000 square feet.
 
    Current operating portfolio 88.6% leased on a weighted average basis.
  Acquired two adjacent life science campuses in South San Francisco for $298.2 million. The properties are fully leased and comprise approximately 489,000 square feet of rentable space with development rights for an additional 946,000 square feet.
 
  Acquired three properties in San Diego, California for a total investment of $64.2 million. The properties were 96.2% leased at acquisition and comprise approximately 243,000 rentable square feet.
 
  Acquired two life science properties in North Carolina’s Research Triangle for a total investment of $14.7 million. The two properties are 89% leased and comprise approximately 79,000 rentable square feet.
 
  Promoted Stephen A. Willey to Vice President, Chief Accounting Officer and Jonathan P. Klassen to Vice President, Assistant General Counsel and Secretary, and
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 85 properties, representing 147 buildings with approximately 12.2 million rentable square feet. The company’s properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

3


 

(BIOMED REALTY TRUST, INC.)
INVESTOR INFORMATION
DECEMBER 31, 2010
             
Company Information
Corporate Headquarters
  Trading Symbols   Transfer Agent   Stock Exchange Listing
17190 Bernardo Center Drive
  BMR   BNY Mellon Shareowner Services   New York Stock Exchange
San Diego, CA 92128
  BMR PrA   480 Washington Boulevard    
(858) 485-9840
      Jersey City, NJ 07310-1900    
(858) 485-9843 (fax)
      (877) 296-3711    
Please visit our corporate website at: www.biomedrealty.com
         
Board of Directors   Senior Management
Alan D. Gold
  Alan D. Gold   Anne L. Hoffman
Chairman
  Chairman and Chief Executive Officer   Senior Vice President,
Barbara R. Cambon
        Leasing & Development
         
 
  R. Kent Griffin, Jr.   Karen A. Sztraicher
Edward A. Dennis, Ph.D.
  President and Chief Operating Officer   Senior Vice President,
 
        Asset Management
         
Richard I. Gilchrist
  Gary A. Kreitzer   Jonathan P. Klassen
 
  Executive Vice President,   Vice President,
Gary A. Kreitzer
    General Counsel and Director  
  Assistant General Counsel and Secretary
         
 
  Matthew G. McDevitt   Kevin M. Simonsen
Theodore D. Roth
  Executive Vice President,   Vice President,
 
    Real Estate     Real Estate Counsel
         
M. Faye Wilson
  Greg N. Lubushkin   Bruce D. Steel
 
  Chief Financial Officer   Managing Director,
 
        BioMed Ventures
 
 
  John P. Bonanno   Stephen A. Willey
 
  Senior Vice President,   Vice President,
 
    Leasing & Development     Chief Accounting Officer
             
Tentative Schedule for Quarterly Results        
First Quarter 2011
  May 4,2011
Second Quarter 2011
  August 3, 2011
Third Quarter 2011
  November 2, 2011
Fourth Quarter 2011
  February 8, 2012

4


 

(BIOMED REALTY TRUST,INC.)
EQUITY RESEARCH COVERAGE
DECEMBER 31, 2010
             
BMO Capital Markets
  Richard C. Anderson / Mark Lutenski   (212) 885-4180 / (212) 885-4197   richard.anderson@bmo.com /
mark.lutenski@bmo.com
 
           
Cowen & Company
  James Sullivan / Michael Gorman   (646) 562-1380 / (646) 562-1381   james.sullivan@cowen.com /
michael.gorman@cowen.com
 
           
Credit Suisse
  Andrew Rosivach / Suzanne Kim   (415) 249-7942 / (415) 249-7943   andrew.rosivach@credit-suisse.com /
suzanne.kim@credit-suisse.com
 
           
FBR Capital Markets
  Sri Nagarajan / Evan Smith   (646) 885-5429 / (646) 885-5431   snagarajan@fbr.com / esmith@fbr.com
 
           
Green Street Advisors
  John Stewart / Michael Knott   (949) 640-8780   jstewart@greenst.com /
mknott@greenst.com
 
           
Jefferies & Co.
  Omotayo Okusanya / Steven Benyik   (212) 336-7076 / (212) 707-6348   tokusanya@jefferies.com /
sbenyik@jefferies.com
 
           
KeyBanc Capital Markets
  Jordan Sadler / Craig Mailman   (917) 368-2280 / (917) 368-2316   jsadler@keybanccm.com /
cmailman@keybanccm.com
 
           
Macquarie Capital (USA)
  Rob Stevenson / Nicholas Yulico   (212) 231-8068 / (212) 231-8028   rob.stevenson@macquarie.com /
nicholas.yulico@macquarie.com
 
           
Raymond James
  Paul D. Puryear / William A. Crow   (727) 567-2253 / (727) 567-5294   paul.puryear@raymondjames.com /
bill.crow@raymondjames.com
 
           
RBC Capital Markets
  David Rodgers / Mike Carroll   (440) 715-2647 / (440) 715-2649   dave.rodgers@rbccm.com /
michael.carroll@rbccm.com
 
           
Robert W. Baird & Co.
  David Aubuchon / Justin Pelham-Webb   (314) 863-4235 / (314) 863-6413   daubuchon@rwbaird.com /
jpelham-webb@rwbaird.com
 
           
Stifel, Nicolaus & Company, Inc.
  John W. Guinee / Erin Aslakson   (443) 224-1307 / (443) 224-1350   jwguinee@stifel.com /
aslaksone@stifel.com
 
           
UBS Securities
  Ross T. Nussbaum / Robert Salisbury   (212) 713-4760 / (212)713-2484   ross.nussbaum@ubs.com /
robert.salisbury@ubs.com
 
           
Wells Fargo Securities, LLC
  Brendan Maiorana / Young Ku   (443) 263-6516 / (443) 263-6564   brendan.maiorana@wachovia.com /
young.ku@wachovia.com

5


 

(BIOMED REALTY TRUST,INC.)
FINANCIAL AND OPERATING HIGHLIGHTS
DECEMBER 31, 2010
(In thousands, except per share and ratio amounts)
                                         
    Three months ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Selected Operating Data
                                       
Total revenues
  $ 105,036     $ 95,733     $ 92,912     $ 92,756     $ 88,171  
 
                                       
EBITDA (1)
    63,491       55,587       53,696       55,590       48,930  
Adjusted EBITDA (1)
    67,910       59,932       58,032       59,952       53,181  
 
                                       
Net operating income — cash basis (2)
    72,390       59,960       59,718       59,173       55,939  
 
                                       
General and administrative expense
    6,379       6,805       6,449       6,269       6,336  
Acquisition related expenses
    665       420       1,819       150       220  
 
                                       
Interest expense
    21,526       21,589       21,870       21,260       20,429  
Capitalized interest
    1,305       1,191       1,301       1,645       1,860  
Interest incurred including swap payments (3)
    22,854       22,791       23,411       23,193       22,634  
 
                                       
Operating margin (4)
    70.1 %     69.3 %     72.2 %     70.9 %     69.9 %
General and administrative expense / Total revenues
    6.1 %     7.1 %     6.9 %     6.8 %     7.2 %
 
                                       
Net income available to common stockholders
    8,521       4,832       4,199       4,299       477  
Net income per share — diluted
  $ 0.06     $ 0.04     $ 0.04     $ 0.04     $ 0.00  
 
                                       
FFO — diluted (5)
    43,581       35,220       33,137       35,487       27,999  
FFO per share — diluted (5)
  $ 0.30     $ 0.28     $ 0.27     $ 0.32     $ 0.28  
 
                                       
AFFO (5)
    39,697       29,698       29,287       30,791       24,245  
AFFO per share — diluted (5)
  $ 0.28     $ 0.23     $ 0.24     $ 0.27     $ 0.24  
 
                                       
Dividend per share — common stock
  $ 0.17     $ 0.17     $ 0.15     $ 0.14     $ 0.14  
 
                                       
FFO payout ratio (6)
    56.7 %     60.7 %     55.6 %     43.8 %     50.0 %
AFFO payout ratio (6)
    60.7 %     73.9 %     62.5 %     51.9 %     58.3 %
 
(1)   For definitions and discussion of EBITDA and adjusted EBITDA, see page 33. For a quantitative reconciliation of the differences between adjusted EBITDA, EBITDA and net income available to common stockholders, see page 13.
 
(2)   For definitions and discussion of net operating income — cash basis, see page 14.
 
(3)   Includes interest paid on cash flow hedges classified as accumulated other comprehensive loss. Excludes ineffectiveness recognized on derivative instruments.
 
(4)   See page 14 for detail.
 
(5)   For definitions and discussion of FFO and AFFO, see page 33. For a quantitative reconciliation of the differences between FFO, AFFO and net income available to common stockholders, see pages 11 and 12.
 
(6)   See page 11 for detail of the FFO payout ratio and page 12 for detail of the AFFO payout ratio.

6


 

(BIOMED REALTY TRUST,INC.)
CAPITALIZATION SUMMARY
DECEMBER 31, 2010
(In thousands, except per share and ratio amounts)
                                                 
            12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Capitalization:
                                               
Total common shares outstanding
            131,047       130,831       113,578       100,312       99,000  
Total units outstanding (1)
            3,001       3,001       3,001       3,038       3,077  
 
                                   
Total common shares and units outstanding
            134,048       133,832       116,579       103,350       102,077  
Common share price at quarter end
          $ 18.65     $ 17.92     $ 16.09     $ 16.54     $ 15.78  
 
                                   
Equity value at quarter end
          $ 2,499,990     $ 2,398,274     $ 1,875,763     $ 1,709,412     $ 1,610,773  
Preferred stock at liquidation value
            230,000       230,000       230,000       230,000       230,000  
Consolidated debt
            1,494,567       1,120,820       1,281,237       1,425,136       1,356,300  
 
                                   
Total capitalization
          $ 4,224,557     $ 3,749,094     $ 3,387,000     $ 3,364,548     $ 3,197,073  
 
                                   
 
                                               
Debt / Total assets
            37.7 %     31.4 %     37.4 %     42.4 %     41.3 %
Debt / Total capitalization
            35.4 %     29.9 %     37.8 %     42.3 %     42.3 %
 
                                               
Coverage Ratios (2):
                                               
Debt / Adjusted EBITDA
            5.5       4.7       5.5       6.0       6.4  
Interest coverage
            3.5       3.1       2.9       3.1       2.9  
Fixed charge coverage
            2.7       2.3       2.2       2.4       2.2  
 
                                               
Total consolidated debt:
                                               
Secured debt / Total assets
            16.6 %     18.5 %     19.4 %     24.3 %     28.0 %
Floating rate debt / Total debt
            26.3 %     1.3 %     13.3 %     38.2 %     47.8 %
Adjusted floating rate debt / Total debt
            16.2 %     0.0 %     1.6 %     10.1 %     18.3 %
Unencumbered real estate / Total real estate
            66.7 %     63.0 %     61.3 %     60.3 %     59.5 %
Unencumbered CABR / Total CABR (3)
            68.7 %     64.8 %     64.8 %     63.8 %     62.3 %
 
                                               
 
  Covenant                                        
Bond covenants (4):
  Requirements                                        
Total Outstanding Debt / Total Assets
  Must be £ 60%     36.1 %     29.7 %     35.4 %            
Secured Debt / Total Assets
  Must be £ 40%     15.8 %     17.4 %     18.2 %            
Consolidated Income Available for Debt Service
/ Annual Debt Service Charge
  Must be ³ 1.5X     3.1       2.6       2.5              
Unencumbered Assets / Unsecured Debt
  Must be ³ 150%     339 %     536 %     373 %            
 
(1)   Includes both operating partnership (OP) and long term incentive plan (LTIP) units outstanding.
 
(2)   For discussion of coverage ratios, see page 33. See page 16 for the calculation of interest and fixed charge coverage ratios. See page 13 for calculation of Adjusted EBITDA.
 
(3)   For discussion of current annualized base rent (CABR), see page 21.
 
(4)   Calculated in accordance with the covenants contained in the Indenture that governs the terms of the Company’s unsecured senior notes due 2020, which is included as an exhibit to the Company’s Form 8-K filed with the SEC on April 30, 2010.

7


 

(BIOMED REALTY TRUST, INC. LOGO)
PORTFOLIO SUMMARY
DECEMBER 31, 2010
                                                                                         
                                                    Unconsolidated                
    Consolidated Portfolio     Partnership Portfolio (1)     Total Portfolio  
            Weighted                                                              
    Gross     Average             Rentable     Percent             Rentable     Percent             Rentable     Percent  
    Book Value     Leased % (2)     Properties     Square Feet     Leased     Properties     Square Feet     Leased     Properties     Square Feet     Leased  
 
  (in thousands)                                                                              
Stabilized (3)
  $ 2,654,438       97.3 %     53       6,518,536       98.6 %     4       72,863       100.0 %     57       6,591,399       98.6 %
Lease up (3)
    732,080       57.3 %     22       2,998,293       65.0 %     3       881,695       44.1 %     25       3,879,988       60.2 %
 
                                                                 
Current operating portfolio
    3,386,517       88.6 %     75       9,516,829       88.0 %     7       954,558       48.3 %     82       10,471,387       84.4 %
Long-term lease up (4)
    290,645       24.0 %     1       1,389,517       24.0 %                 n/a       1       1,389,517       24.0 %
 
                                                                 
Total operating portfolio
    3,677,162       83.5 %     76       10,906,346       79.9 %     7       954,558       48.3 %     83       11,860,904       77.3 %
Development (5)
    41,990       100.0 %     1       176,000       100.0 %                 n/a       1       176,000       100.0 %
Redevelopment (5)
                            n/a                   n/a                   n/a  
Pre-development (5)
    25,651             1       152,145                         n/a       1       152,145        
 
                                                                 
Total property portfolio
    3,744,803       83.1 %     78       11,234,491       79.1 %     7       954,558       48.3 %     85       12,189,049       76.7 %
 
                                                                         
Development potential (5)
    133,288                       2,626,000                                               2,626,000          
 
                                                                                 
Total portfolio
  $ 3,878,091                       13,860,491                                               14,815,049          
 
                                                                                 
 
(1)   Includes 72,863 rentable square feet of McKellar Court (22%) and 881,695 rentable square feet of PREI joint venture properties (20%). See page 25 for additional detail.
 
(2)   Calculated based on gross book value for each asset multiplied by the percentage leased.
 
(3)   See pages 22-23 for detail of consolidated portfolio, page 25 for detail of the unconsolidated partnership portfolio, and page 34 for definitions of terms.
 
(4)   Includes Pacific Research Center.
 
(5)   See page 24 for detail of consolidated portfolio, page 25 for detail of the unconsolidated partnership portfolio, and page 34 for definitions of terms.

8


 

(BIOMED REALTY TRUST, INC. LOGO)
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2010

(In thousands)
                                         
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Assets                                        
Investments in real estate, net
  $ 3,536,114     $ 3,207,957     $ 3,075,150     $ 3,015,632     $ 2,971,767  
Investments in unconsolidated partnerships
    57,265       58,565       59,459       55,968       56,909  
Cash and cash equivalents
    21,467       20,687       21,339       36,800       19,922  
Restricted cash
    9,971       12,384       11,547       15,304       15,355  
Accounts receivable, net
    5,874       7,333       2,859       2,501       4,135  
Accrued straight-line rents, net
    106,905       102,567       96,298       88,981       82,066  
Acquired above-market leases, net
    30,566       3,796       2,436       2,741       3,047  
Deferred leasing costs, net
    125,060       88,828       80,373       81,539       83,274  
Deferred loan costs, net
    11,499       12,394       12,825       12,124       8,123  
Other assets
    55,033       58,042       65,935       48,605       38,676  
 
                             
Total assets
  $ 3,959,754     $ 3,572,553     $ 3,428,221     $ 3,360,195     $ 3,283,274  
 
                             
Liabilities and Equity                                        
Liabilities:
                                       
Mortgage notes payable, net
  $ 657,922     $ 662,522     $ 664,867     $ 667,175     $ 669,454  
Secured term loan
                      150,000       250,000  
Exchangeable senior notes due 2026, net
    19,522       19,432       21,396       38,804       44,685  
Exchangeable senior notes due 2030
    180,000       180,000       180,000       180,000        
Unsecured senior notes due 2020, net
    247,571       247,523       247,475              
Unsecured line of credit
    392,450       14,050       170,500       394,564       397,666  
Security deposits
    11,749       10,883       10,352       8,003       7,929  
Dividends and distributions payable
    27,029       26,992       21,728       18,710       18,531  
Accounts payable, accrued expenses and other liabilities
    98,826       75,319       50,720       49,532       47,388  
Derivative instruments
    3,826       5,453       6,631       9,568       12,551  
Acquired below-market leases, net
    7,963       8,031       9,039       10,062       11,138  
 
                             
Total liabilities
    1,646,858       1,250,205       1,382,708       1,526,418       1,459,342  
Equity:
                                       
Stockholders’ equity:
                                       
Preferred stock
    222,413       222,413       222,413       222,413       222,413  
Common stock
    1,310       1,308       1,136       1,003       990  
Additional paid-in capital
    2,371,488       2,369,952       2,079,153       1,858,212       1,843,551  
Accumulated other comprehensive loss
    (70,857 )     (73,840 )     (77,049 )     (81,380 )     (85,183 )
Dividends in excess of earnings
    (221,176 )     (207,419 )     (190,010 )     (177,173 )     (167,429 )
 
                             
Total stockholders’ equity
    2,303,178       2,312,414       2,035,643       1,823,075       1,814,342  
Noncontrolling interests
    9,718       9,934       9,870       10,702       9,590  
 
                             
Total equity
    2,312,896       2,322,348       2,045,513       1,833,777       1,823,932  
 
                             
Total liabilities and equity
  $ 3,959,754     $ 3,572,553     $ 3,428,221     $ 3,360,195     $ 3,283,274  
 
                             

9


 

(BIOMED REALTY TRUST, INC. LOGO)
CONSOLIDATED STATEMENTS OF INCOME
DECEMBER 31, 2010

(In thousands, except share and per share data)
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Revenues:
                                       
Rental
  $ 79,157     $ 72,971     $ 72,380     $ 70,600     $ 67,294  
Tenant recoveries
    23,580       22,723       20,273       20,826       19,895  
Other income
    2,299       39       259       1,330       982  
 
                             
Total revenues
    105,036       95,733       92,912       92,756       88,171  
 
                             
Expenses:
                                       
Rental operations
    20,935       19,998       17,077       17,851       17,675  
Real estate taxes
    9,745       9,408       8,703       8,722       8,532  
Depreciation and amortization
    32,196       27,774       26,469       28,915       26,853  
General and administrative
    6,379       6,805       6,449       6,269       6,336  
Acquisition related expenses
    665       420       1,819       150       220  
 
                             
Total expenses
    69,920       64,405       60,517       61,907       59,616  
 
                             
Income from operations
    35,116       31,328       32,395       30,849       28,555  
Equity in net loss of unconsolidated partnerships
    (958 )     (308 )     (100 )     (277 )     (506 )
Interest income
    46       55       51       20       82  
Interest expense
    (21,526 )     (21,589 )     (21,870 )     (21,260 )     (20,429 )
Gain/(loss) on derivative instruments
    181       (287 )     (497 )     150       (86 )
Gain/(loss) on extinguishment of debt
    81       (22 )     (1,444 )     (821 )     (2,888 )
 
                             
Net income
    12,940       9,177       8,535       8,661       4,728  
Net income attributable to noncontrolling interests
    (178 )     (104 )     (95 )     (121 )     (10 )
 
                             
Net income attributable to Company
    12,762       9,073       8,440       8,540       4,718  
Preferred stock dividends
    (4,241 )     (4,241 )     (4,241 )     (4,241 )     (4,241 )
 
                             
Net income available to common stockholders
  $ 8,521     $ 4,832     $ 4,199     $ 4,299     $ 477  
 
                             
 
Net income per share available to common stockholders:
                                       
Basic and diluted earnings per share
  $ 0.06     $ 0.04     $ 0.04     $ 0.04     $ 0.00  
 
                             
 
Weighted-average common shares outstanding:
                                       
Basic
    129,599,798       112,910,694       109,707,274       98,229,996       97,706,262  
 
                             
Diluted
    132,601,048       115,911,944       113,956,077       102,577,329       101,666,673  
 
                             

10


 

(BIOMED REALTY TRUST, INC. LOGO)
FFO (1)
DECEMBER 31, 2010

(In thousands, except per share and ratio amounts)
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Reconciliation of net income available to common stockholders to funds from operations (FFO):
                                       
Net income available to common stockholders
  $ 8,521     $ 4,832     $ 4,199     $ 4,299     $ 477  
Adjustments:
                                       
Noncontrolling interests in operating partnership
    188       122       109       127       30  
Depreciation & amortization — unconsolidated partnerships
    1,014       835       694       662       662  
Depreciation & amortization — consolidated entities
    32,196       27,774       26,469       28,915       26,853  
Depreciation & amortization — allocable to noncontrolling interests of consolidated joint ventures
    (26 )     (24 )     (22 )     (22 )     (23 )
 
                             
FFO
  $ 41,893     $ 33,539     $ 31,449     $ 33,981     $ 27,999  
 
                             
 
FFO per share
  $ 0.31     $ 0.29     $ 0.28     $ 0.33     $ 0.28  
 
                             
 
FFO
  $ 41,893     $ 33,539     $ 31,449     $ 33,981     $ 27,999  
Interest expense — exchangeable senior notes due 2030 (2)
    1,688       1,681       1,688       1,506        
 
                             
FFO — diluted
  $ 43,581     $ 35,220     $ 33,137     $ 35,487     $ 27,999  
 
                             
FFO per share diluted (2)
  $ 0.30     $ 0.28     $ 0.27     $ 0.32     $ 0.28  
 
                             
Dividends and distributions declared per common share
  $ 0.17     $ 0.17     $ 0.15     $ 0.14     $ 0.14  
 
                             
FFO payout ratio
    56.7 %     60.7 %     55.6 %     43.8 %     50.0 %
 
                             
 
Weighted-average common shares outstanding diluted (3)
    133,905,635       117,139,883       113,956,077       102,577,329       101,666,673  
Dilutive effect of exchangeable notes due 2030 (2)
    9,914,076       9,914,076       9,914,076       9,914,076        
 
                             
Weighted-average common shares outstanding diluted — FFO
    143,819,711       127,053,959       123,870,153       112,491,405       101,666,673  
 
                             
 
(1)   For definitions and discussion of FFO see page 33.
 
(2)   The calculation of FFO per share diluted includes the assumed issuance of common stock pursuant to the exchange provision of the exchangeable senior notes due 2030, which is dilutive based on the “if converted” method for all periods presented since the original issuance in January 2010. Under the if converted method, if the add back of interest charges relating to the exchangeable senior notes due 2030 divided by the corresponding number of common shares issuable upon exchange is dilutive, the potentially issuable shares are included in the calculation of FFO per diluted share.
 
(3)   The three months ended December 31, 2010 and September 30, 2010 include 1,304,587 and 1,227,939 shares of unvested restricted stock, respectively, which are considered anti-dilutive for purposes of calculating diluted earnings per share.

11


 

(BIOMED REALTY TRUST, INC LOGO)
AFFO (1)
DECEMBER 31, 2010

(In thousands, except per share and ratio amounts)
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Reconciliation of FFO to adjusted funds from operations (AFFO):
                                       
FFO — diluted
  $ 43,581     $ 35,220     $ 33,137     $ 35,487     $ 27,999  
Adjustments:
                                       
Recurring capital expenditures and tenant improvements (2)
    (2,867 )     (3,208 )     (1,817 )     (2,834 )     (978 )
Leasing commissions
    (1,799 )     (1,507 )     (1,494 )     (424 )     (3,471 )
(Gain)/loss on extinguishment of debt
    (81 )     22       1,444       821       2,888  
(Gain)/loss on derivative instruments
    (181 )     287       497       (150 )     86  
Amortization of deferred interest costs
    1,771       1,776       1,781       1,786       1,791  
Amortization of deferred loan costs
    1,080       1,039       1,040       1,143       784  
Amortization of fair-value of debt acquired
    (522 )     (476 )     (474 )     (467 )     (467 )
Amortization of debt discount
    137       179       208       177       427  
Amortization of lease incentive
    587       587       535       500       328  
Depreciation included in general and administrative expense
    376       363       359       347       396  
Non-cash equity compensation
    1,673       1,802       1,725       1,789       1,462  
Straight line rents
    (5,629 )     (6,113 )     (7,151 )     (6,733 )     (6,358 )
Share of unconsolidated partnership adjustments (3)
    146       423       433       243       244  
Fair-value lease revenue
    1,425       (696 )     (936 )     (894 )     (886 )
 
                             
AFFO
  $ 39,697     $ 29,698     $ 29,287     $ 30,791     $ 24,245  
 
                             
AFFO per share — diluted
  $ 0.28     $ 0.23     $ 0.24     $ 0.27     $ 0.24  
 
                             
Dividends and distributions declared per common share
  $ 0.17     $ 0.17     $ 0.15     $ 0.14     $ 0.14  
 
                             
AFFO payout ratio
    60.7 %     73.9 %     62.5 %     51.9 %     58.3 %
 
                             
 
(1)   For definitions and discussion of AFFO see page 33.
 
(2)   Excludes value-enhancing / first generation capital expenditures and tenant improvements.
 
(3)   Share of unconsolidated partnership adjustments includes the Company’s share of amortization of deferred loan costs, lease incentives, straight line rents, and fair-value lease revenue.

12


 

(BIOMED REALTY TRUST, INC LOGO)
RECONCILIATION OF EBITDA (1)
DECEMBER 31, 2010

(In thousands)
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Reconciliation of net income available to common stockholders to earnings before interest, taxes, depreciation and amortization (EBITDA):
                                       
Net income available to common stockholders
  $ 8,521     $ 4,832     $ 4,199     $ 4,299     $ 477  
Interest expense
    21,526       21,589       21,870       21,260       20,429  
Interest expense — unconsolidated partnerships
    234       557       464       454       509  
Depreciation & amortization — consolidated entities
    32,196       27,774       26,469       28,915       26,853  
Depreciation & amortization — unconsolidated partnerships
    1,014       835       694       662       662  
 
                             
EBITDA
    63,491       55,587       53,696       55,590       48,930  
Noncontrolling interests
    178       104       95       121       10  
Preferred dividends
    4,241       4,241       4,241       4,241       4,241  
 
                             
Adjusted EBITDA
  $ 67,910     $ 59,932     $ 58,032     $ 59,952     $ 53,181  
 
                             
 
(1)   For definitions and discussion of EBITDA and Adjusted EBITDA, see page 33.

13


 

(BIOMED REALTY TRUST, INC LOGO)
RECONCILIATION OF NET OPERATING INCOME (1)
DECEMBER 31, 2010

(Dollars in thousands)
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Net income
  $ 12,940     $ 9,177     $ 8,535     $ 8,661     $ 4,728  
Equity in net loss of unconsolidated partnerships
    958       308       100       277       506  
Interest expense
    21,526       21,589       21,870       21,260       20,429  
Interest income
    (46 )     (55 )     (51 )     (20 )     (82 )
(Gain)/loss on derivative instruments
    (181 )     287       497       (150 )     86  
(Gain)/loss on extinguishment of debt
    (81 )     22       1,444       821       2,888  
 
                             
Income from operations
    35,116       31,328       32,395       30,849       28,555  
Depreciation and amortization
    32,196       27,774       26,469       28,915       26,853  
General and administrative
    6,379       6,805       6,449       6,269       6,336  
Acquisition related expenses
    665       420       1,819       150       220  
 
                             
Consolidated net operating income
  $ 74,356     $ 66,327     $ 67,132     $ 66,183     $ 61,964  
 
                             
 
                                       
Revenues:
                                       
Rental
  $ 79,157     $ 72,971     $ 72,380     $ 70,600     $ 67,294  
Tenant recoveries
    23,580       22,723       20,273       20,826       19,895  
Other income
    2,299       39       259       1,330       982  
 
                             
Total revenues
    105,036       95,733       92,912       92,756       88,171  
 
                                       
Expenses:
                                       
Rental operations
    20,935       19,998       17,077       17,851       17,675  
Real estate taxes
    9,745       9,408       8,703       8,722       8,532  
 
                             
Total operating expenses
    30,680       29,406       25,780       26,573       26,207  
 
                             
Consolidated net operating income
  $ 74,356     $ 66,327     $ 67,132     $ 66,183     $ 61,964  
 
                             
Consolidated net operating income — cash basis (2)
  $ 72,390     $ 59,960     $ 59,718     $ 59,173     $ 55,939  
 
                             
 
                                       
Operating margin (3)
    70.1 %     69.3 %     72.2 %     70.9 %     69.9 %
Operating expense recovery (4)
    76.9 %     77.3 %     78.6 %     78.4 %     75.9 %
 
(1)   For a definition and discussion of net operating income, see page 33.
 
(2)   Consolidated net operating income — cash basis is calculated as (consolidated net operating income — straight line rents — fair value lease revenue — lease incentive revenue — bad debt expense).
 
(3)   Operating margin is calculated as ((rental revenues + tenant recovery revenues - rental operations — real estate taxes) / (rental revenues + tenant recovery revenues)).
 
(4)   Operating expense recovery is calculated as (tenant recovery revenues / (rental operations + real estate taxes)).

14


 

(BIOMED REALTY TRUST, INC LOGO)
INTEREST EXPENSE
DECEMBER 31, 2010

(Dollars in thousands)
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Mortgage notes payable
  $ 11,829     $ 11,838     $ 11,845     $ 11,858     $ 11,953  
Secured term loan
                222       1,170       1,209  
Exchangeable senior notes due 2026
    223       234       444       457       1,055  
Exchangeable senior notes due 2030
    1,688       1,681       1,688       1,506        
Unsecured senior notes due 2020
    3,827       3,829       2,637              
Unsecured line of credit
    1,101       1,004       933       1,152       1,335  
Derivative instruments
    1,697       1,676       2,847       4,123       4,202  
 
                             
Interest expense — cash basis
  $ 20,365     $ 20,262     $ 20,616     $ 20,266     $ 19,754  
 
                             
 
                                       
Non cash interest expense
                                       
Amortization of fair-value of debt acquired
    (522 )     (476 )     (474 )     (467 )     (467 )
Amortization of debt discount on exchangeable senior notes due 2026
    89       132       175       177       427  
Amortization of debt discount on unsecured senior notes due 2020
    48       47       33              
Amortization of deferred loan costs
    1,080       1,039       1,040       1,143       784  
Amortization of deferred interest costs
    1,771       1,776       1,781       1,786       1,791  
Capitalized interest
    (1,305 )     (1,191 )     (1,301 )     (1,645 )     (1,860 )
 
                             
Interest expense
  $ 21,526     $ 21,589     $ 21,870     $ 21,260     $ 20,429  
 
                             

15


 

(BIOMED REALTY TRUST INC LOGO)
COVERAGE RATIOS (1)
DECEMBER 31, 2010

 
(In thousands,except ratios)
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Interest coverage ratio
                                       
Adjusted EBITDA
  $ 67,910     $ 59,932     $ 58,032     $ 59,952     $ 53,181  
Interest expense:
                                       
Interest expense
    21,526       21,589       21,870       21,260       20,429  
Interest expense — unconsolidated partnerships
    234       557       464       454       509  
Amortization of deferred interest costs
    (1,771 )     (1,776 )     (1,781 )     (1,786 )     (1,791 )
Amortization of deferred loan costs
    (1,080 )     (1,039 )     (1,040 )     (1,143 )     (784 )
Amortization of debt discount
    (137 )     (179 )     (208 )     (177 )     (427 )
Amortization of fair-value of debt acquired
    522       476       474       467       467  
 
                             
Total interest expense
  $ 19,294     $ 19,628     $ 19,779     $ 19,075     $ 18,403  
 
                             
 
                                       
Interest coverage ratio
    3.5       3.1       2.9       3.1       2.9  
 
                             
 
                                       
Fixed charge coverage ratio
                                       
Adjusted EBITDA
  $ 67,910     $ 59,932     $ 58,032     $ 59,952     $ 53,181  
Fixed charges:
                                       
Interest expense
    21,526       21,589       21,870       21,260       20,429  
Interest expense — unconsolidated partnerships
    234       557       464       454       509  
Amortization of deferred interest costs
    (1,771 )     (1,776 )     (1,781 )     (1,786 )     (1,791 )
Amortization of deferred loan costs
    (1,080 )     (1,039 )     (1,040 )     (1,143 )     (784 )
Amortization of debt discount
    (137 )     (179 )     (208 )     (177 )     (427 )
Amortization of fair-value of debt acquired
    522       476       474       467       467  
Principal payments
    1,912       1,868       1,834       1,812       1,773  
Principal payments — unconsolidated partnerships
                            8  
Preferred dividends
    4,241       4,241       4,241       4,241       4,241  
 
                             
Total fixed charges
  $ 25,447     $ 25,737     $ 25,854     $ 25,128     $ 24,425  
 
                             
 
                                       
Fixed charge coverage ratio
    2.7       2.3       2.2       2.4       2.2  
 
                             
 
 (1)   For a discussion of coverage ratios, see page 33.

16


 

(BIOMED REALTY TRUST INC LOGO)
DEBT SUMMARY
DECEMBER 31, 2010

 
(Dollars in thousands)
                                                 
                            Unamortized              
    Stated     Effective     Principal     Premium /     Carrying     Maturity  
Consolidated debt:   Rate     Rate     Balance     (Discount)     Value     Date  
Mortgage notes payable (1):
                                               
Ardentech Court
    7.25 %     5.06 %   $ 4,237     $ 138     $ 4,375       07/12  
Center for Life Science | Boston
    7.75 %     7.75 %     345,577             345,577       06/14  
500 Kendall Street (Kendall D)
    6.38 %     5.45 %     64,230       3,284       67,514       12/18  
6828 Nancy Ridge Drive
    7.15 %     5.38 %     6,488       199       6,687       09/12  
Road to the Cure
    6.70 %     5.78 %     14,696       380       15,076       01/14  
Science Center Drive
    7.65 %     5.04 %     10,800       164       10,964       07/11  
Shady Grove Road
    5.97 %     5.97 %     147,000             147,000       09/16  
Sidney Street
    7.23 %     5.11 %     27,395       816       28,211       06/12  
Sorrento West
    7.42 %     2.72 %     13,247       558       13,805       11/11  
9865 Towne Centre Drive
    7.95 %     7.95 %     17,636             17,636       06/13  
900 Uniqema Boulevard
    8.61 %     5.61 %     1,011       66       1,077       05/15  
 
                                   
Total / weighted average on fixed rate mortgages
    7.16 %     6.78 %     652,317       5,605       657,922          
 
                                               
Fixed rate debt:
                                               
Unsecured exchangeable senior notes due 2026
    4.50 %     6.45 %     19,800       (278 )     19,522       10/26  
Unsecured exchangeable senior notes due 2030
    3.75 %     3.75 %     180,000             180,000       01/30  
Unsecured senior notes due 2020
    6.13 %     6.27 %     250,000       (2,429 )     247,571       04/20  
 
                                   
Total / weighted average fixed rate debt
    6.32 %     6.16 %     1,102,117       2,898       1,105,015          
 
                                               
Variable rate debt:
                                               
$720 million unsecured line of credit
    1.35 %     1.35 %     392,450             392,450       08/11  
 
                                   
Total / weighted average variable rate debt
    1.35 %     1.35 %     392,450             392,450          
 
                                   
 
                                               
Total / weighted average consolidated debt
    5.01 %     4.90 %   $ 1,494,567     $ 2,898     $ 1,497,465          
 
                                   
 
                                               
Share of unconsolidated partnership debt:
                                               
PREI secured loan (20%) (variable)
    3.76 %     3.76 %   $ 40,650     $     $ 40,650       02/12  
PREI secured construction loan (20%) (variable)
    1.77 %     1.77 %     40,481             40,481       08/11  
 
                                   
Total / weighted average share of unconsolidated partnership debt
    2.77 %     2.77 %     81,131             81,131          
 
                                   
 
                                               
Total / weighted average consolidated and share of unconsolidated
partnership debt
    4.90 %     4.79 %   $ 1,575,698     $ 2,898     $ 1,578,596          
 
                                   
 
 (1)   Subsequent to quarter end the Road to the Cure note was voluntarily prepaid in full prior to its scheduled maturity.

17


 

(BIOMED REALTY TRUST INC LOGO)
DEBT ANALYSIS
DECEMBER 31, 2010

 
(Dollars in thousands)
Secured and Unsecured Debt Analysis
 
                                 
                    Weighted     Weighted  
            Percentage     Average     Average  
    Principal     of Principal     Stated     Effective  
    Balance     Balance     Interest Rate     Interest Rate  
Secured debt
  $ 652,317       43.6 %     7.16 %     6.78 %
 
                               
Unsecured debt
    842,250       56.4 %     3.35 %     4.22 %
 
                       
 
                               
Total consolidated debt
  $ 1,494,567       100.0 %     5.01 %     5.34 %
 
                       
Fixed and Variable Rate Debt Analysis
 
                                 
                    Weighted     Weighted  
            Percentage     Average     Average  
    Principal     of Principal     Stated     Effective  
    Balance     Balance     Interest Rate     Interest Rate  
Fixed rate debt
  $ 1,102,117       73.7 %     6.32 %     6.16 %
 
                               
Variable rate debt — hedged
    150,000       10.0 %     1.35 %     5.70 %
 
                               
Variable rate debt — unhedged
    242,450       16.2 %     1.35 %     1.35 %
 
                       
 
                               
Total consolidated debt
  $ 1,494,567       100.0 %     5.01 %     5.34 %
 
                       

18


 

(BIOMED REALTY TRUST INC LOGO)
DEBT MATURITIES
DECEMBER 31, 2010

 
(In thousands)
Weighted average debt maturity is 6 years for consolidated debt.
                                                         
    2011     2012     2013     2014     2015     Thereafter     Total  
Consolidated debt:
                                                       
 
                                                       
Fixed rate debt:
                                                       
Fixed rate mortgages
  $ 31,842     $ 45,177     $ 25,688     $ 352,822     $ 6,253     $ 190,535     $ 652,317  
Unsecured exchangeable senior notes due 2026 (1)
                                  19,800       19,800  
Unsecured exchangeable senior notes due 2030 (2)
                                  180,000       180,000  
Unsecured senior notes due 2020
                                  250,000       250,000  
 
                                         
Total fixed rate debt
    31,842       45,177       25,688       352,822       6,253       640,335       1,102,117  
 
                                                       
Variable rate debt:
                                                       
$720 million unsecured line of credit (3)
    392,450                                     392,450  
 
                                         
Total variable rate debt
    392,450                                     392,450  
 
                                         
 
                                                       
Total consolidated debt
  $ 424,292     $ 45,177     $ 25,688     $ 352,822     $ 6,253     $ 640,335     $ 1,494,567  
 
                                         
Share of unconsolidated partnership debt:
                                                       
PREI secured loan (20%) (variable) (4)
  $     $ 40,650     $     $     $     $     $ 40,650  
PREI secured construction loan (20%) (variable) (5)
    40,481                                     40,481  
 
                                         
Share of total unconsolidated partnership debt
  $ 40,481     $ 40,650     $     $     $     $     $ 81,131  
 
                                         
 
                                                       
Total consolidated and share of unconsolidated partnership debt
  $ 464,773     $ 85,827     $ 25,688     $ 352,822     $ 6,253     $ 640,335     $ 1,575,698  
 
                                         
 
(1)   The holders of the unsecured exchangeable senior notes due 2026 (the “2026 Notes”) have the right to require the Company to repurchase the 2026 Notes, in whole or in part, for cash on each of October 1, 2011, October 1, 2016 and October 1, 2021, or upon the occurrence of a designated event, in each case for a repurchase price equal to 100% of the principal amount of the 2026 Notes plus accrued and unpaid interest.
 
(2)    The holders of the unsecured exchangeable senior notes due 2030 (the “2030 Notes”) have the right to require the Company to repurchase the 2030 Notes, in whole or in part, for cash on each of January 15, 2015, January 15, 2020 and January 15, 2025, or upon the occurrence of a designated event, in each case for a repurchase price equal to 100% of the principal amount of the 2030 Notes plus accrued and unpaid interest.
 
 (3)   The maturity date may be extended to August 1, 2012 after satisfying certain conditions.
 
 (4)   Subsequent to quarter end the maturity date was extended to February 2012.
 
 (5)   Subsequent to quarter end the maturity date was extended to August 2011.

19


 

(BIOMED REALTY TRUST INC LOGO)
COMMON AND PREFERRED STOCK DATA
DECEMBER 31, 2010

 
(Shares in thousands)
SUMMARY OF COMMON SHARES
 
                                         
    Three Months Ended
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Earnings per share
                                       
Weighted average common shares outstanding
    129,600       112,911       109,707       98,229       97,707  
Weighted average OP and LTIP units outstanding
    3,001       3,001       3,019       3,058       3,081  
Dilutive effect of restricted stock
                1,230       1,290       879  
 
                             
Diluted common shares — EPS
    132,601       115,912       113,956       102,577       101,667  
 
                             
 
Funds from operations
                                       
Weighted average common shares outstanding
    129,600       112,911       109,707       98,229       97,707  
Weighted average OP and LTIP units outstanding
    3,001       3,001       3,019       3,058       3,081  
Dilutive effect of restricted stock
    1,305       1,228       1,230       1,290       879  
Dilutive effect of exchangeable senior notes due 2030
    9,914       9,914       9,914       9,914        
 
                             
Diluted common shares — FFO
    143,820       127,054       123,870       112,491       101,667  
 
                             
 
Closing common shares, OP and LTIP units outstanding
    134,048       133,832       116,579       103,350       102,077  
Preferred shares outstanding
    9,200       9,200       9,200       9,200       9,200  
 
High price
  $ 19.50     $ 19.25     $ 19.50     $ 17.88     $ 16.59  
Low price
  $ 16.64     $ 14.79     $ 15.04     $ 13.36     $ 12.62  
Average closing price
  $ 18.21     $ 17.52     $ 17.39     $ 15.70     $ 14.16  
Closing price
  $ 18.65     $ 17.92     $ 16.09     $ 16.54     $ 15.78  
Dividends per share — annualized
  $ 0.68     $ 0.68     $ 0.60     $ 0.56     $ 0.56  
Closing dividend yield — annualized
    3.6 %     3.8 %     3.7 %     3.4 %     3.5 %
DIVIDENDS PER SHARE
 
                                         
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Common Stock — BMR
                                       
Amount
  $ 0.17     $ 0.17     $ 0.15     $ 0.14     $ 0.14  
Declared
  December 15, 2010     September 15, 2010     June 15, 2010     March 15, 2010     December 15, 2009  
Record
  December 31, 2010     September 30, 2010     June 30, 2010     March 31, 2010     December 31, 2009  
Paid
  January 17, 2011     October 15, 2010     July 15, 2010     April 15, 2010     January 15, 2010  
 
Preferred Stock — BMR PrA
                                       
Amount
  $ 0.46094     $ 0.46094     $ 0.46094     $ 0.46094     $ 0.46094  
Declared
  December 15, 2010     September 15, 2010     June 15, 2010     March 15, 2010     December 15, 2009  
Record
  December 31, 2010     September 30, 2010     June 30, 2010     March 31, 2010     December 31, 2009  
Paid
  January 17, 2011     October 15, 2010     July 15, 2010     April 15, 2010     January 15, 2010  

20


 

(BIOMED REALTY TRUST,INC.LOGO)
MARKET SUMMARY
DECEMBER 31, 2010
                                                         
            Current (1)     Expiration (2)  
                            Annualized                     Annualized  
    Leased             Percent of     Base Rent             Percent of     Base Rent  
    Square     Annualized     Annualized     per Leased     Annualized     Annualized     per Leased  
Market   Feet     Base Rent     Base Rent     Sq Ft     Base Rent     Base Rent     Sq Ft  
            (in thousands)                     (in thousands)                  
Boston
    2,201,857     $ 118,915       33.6 %   $ 54.01     $ 128,303       30.4 %   $ 58.27  
San Francisco
    1,596,534       56,166       15.8 %     35.18       70,260       16.6 %     44.01  
San Diego
    1,713,821       54,925       15.5 %     32.05       69,793       16.5 %     40.72  
Maryland
    1,502,766       54,402       15.4 %     36.20       70,858       16.8 %     47.15  
New York / New Jersey
    1,060,042       35,512       10.0 %     33.50       44,387       10.5 %     41.87  
Pennsylvania
    710,005       15,707       4.4 %     22.12       17,213       4.1 %     24.24  
Seattle
    180,136       7,711       2.2 %     42.81       9,160       2.2 %     50.85  
University Related — Other
    381,390       11,068       3.1 %     29.02       12,128       2.9 %     31.80  
 
                                         
Total portfolio / weighted average
    9,346,551     $ 354,406       100.0 %   $ 37.92     $ 422,102       100.0 %   $ 45.16  
 
                                         
 
(1)   Current annualized base rent is the monthly contractual rent as of the current quarter ended, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.
 
(2)   Annualized base rent at expiration is the monthly contractual rent as of date of expiration of the applicable lease (not including any extension options(s)), multiplied by 12 months.

21


 

(BIOMED REALTY TRUST,INC.LOGO)
PROPERTY LISTING — CONSOLIDATED PORTFOLIO
DECEMBER 31, 2010
                                                             
                        Rentable     Percent of     Leased        
            Property           Square     Rentable     Square     Percent Leased  
    Property   Acquisition Date   Status (1)   Buildings     Feet     Sq Ft     Feet     12/31/10     9/30/10  
   
Boston
                                                       
1  
Albany Street
  May 31, 2005   Stabilized     2       75,003       0.7 %     75,003       100.0 %     100.0 %
2  
Center for Life Science | Boston
  November 17, 2006   Stabilized     1       704,159       6.8 %     641,438       91.1 %     91.1 %
3  
Charles Street
  April 7, 2006   Stabilized     1       47,912       0.4 %     47,912       100.0 %     100.0 %
4  
Coolidge Avenue
  April 5, 2005   Lease Up     1       37,400       0.3 %     12,972       34.7 %     34.7 %
5  
21 Erie Street
  May 31, 2005   Stabilized     1       48,627       0.4 %     48,627       100.0 %     100.0 %
6  
40 Erie Street
  May 31, 2005   Stabilized     1       100,854       0.9 %     100,854       100.0 %     100.0 %
7  
47 Erie Street Parking Structure
  May 31, 2005   Stabilized     1     447 Stalls       n/a     447 Stalls       n/a       n/a  
8  
Fresh Pond Research Park
  April 5, 2005   Lease Up     6       90,702       0.8 %     51,546       56.8 %     73.5 %
9  
675 W. Kendall Street (Kendall A)
  May 31, 2005   Stabilized     1       302,919       2.7 %     298,871       98.7 %     98.7 %
10  
500 Kendall Street (Kendall D)
  May 31, 2005   Stabilized     1       349,325       3.1 %     344,097       98.5 %     98.5 %
11  
Sidney Street
  May 31, 2005   Stabilized     1       191,904       1.7 %     191,904       100.0 %     100.0 %
12  
Vassar Street
  May 31, 2005   Lease Up     1       52,520       0.5 %                  
   
 
                                           
   
Total Boston
            18       2,001,325       18.3 %     1,813,224       90.6 %     91.4 %
   
 
                                           
   
 
                                                       
   
San Francisco
                                                       
13  
Ardentech Court
  November 18, 2004   Stabilized     1       55,588       0.5 %     55,588       100.0 %     100.0 %
14  
Ardenwood Venture (2)
  June 14, 2006   Lease Up     1       72,500       0.6 %     27,620       38.1 %     38.1 %
15  
Bayshore Boulevard
  August 17, 2004   Stabilized     3       183,344       1.6 %     183,344       100.0 %     100.0 %
16  
Bridgeview Technology Park I
  September 10, 2004   Lease Up     2       201,567       1.8 %     125,144       62.1 %     62.1 %
17  
Bridgeview Technology Park II
  March 16, 2005   Lease Up     1       50,400       0.4 %     25,200       50.0 %     50.0 %
18  
Dumbarton Circle
  May 27, 2005   Stabilized     3       44,000       0.4 %     44,000       100.0 %     100.0 %
19  
Eccles Avenue
  December 1, 2005   Pre-development     1       152,145       1.4 %                  
20  
Forbes Boulevard
  September 5, 2007   Lease Up     1       237,984       2.1 %     118,992       50.0 %     100.0 %
21  
Industrial Road
  August 17, 2004   Lease Up     1       171,965       1.5 %     144,105       83.8 %     83.8 %
22  
Gateway Business Park
  October 26, 2010   Stabilized     7       284,013       2.5 %     284,013       100.0 %     n/a  
23  
Kaiser Drive
  August 25, 2005   Lease Up     1       87,953       0.8 %     50,000       56.8 %     56.8 %
24  
Pacific Research Center
  July 11, 2006   Lease Up     10       1,389,517       12.4 %     333,641       24.0 %     16.2 %
25  
Science Center at Oyster Point
  October 26, 2010   Stabilized     2       204,887       1.8 %     204,887       100.0 %     n/a  
   
 
                                           
   
Total San Francisco
            34       3,135,863       27.8 %     1,596,534       50.9 %     42.3 %
   
 
                                           
   
 
                                                       
   
San Diego
                                                       
26  
Balboa Avenue
  August 13, 2004   Stabilized     1       35,344       0.3 %     35,344       100.0 %     100.0 %
27  
Bernardo Center Drive
  August 13, 2004   Stabilized     1       61,286       0.5 %     61,286       100.0 %     100.0 %
28  
4570 Executive Drive
  September 17, 2010   Stabilized     1       125,219       1.1 %     125,219       100.0 %     100.0 %
29  
4775 / 4785 Executive Drive
  July 15, 2010   Lease Up     1       62,896       0.6 %                  
30  
Faraday Avenue
  September 19, 2005   Stabilized     1       28,704       0.3 %     28,704       100.0 %     100.0 %
31  
Gazelle Court
  March 30, 2010   Development     1       176,000       1.6 %     176,000       100.0 %     100.0 %
32  
3525 John Hopkins Court
  December 28, 2010   Stabilized     1       48,306       0.4 %     48,306       100.0 %     n/a  
33  
3545-3575 John Hopkins Court
  August 16, 2006   Lease Up     1       72,192       0.6 %     21,470       29.7 %     29.7 %
34  
6114-6154 Nancy Ridge Drive
  May 2, 2007   Stabilized     3       196,557       1.7 %     196,557       100.0 %     100.0 %
35  
6828 Nancy Ridge Drive
  April 21, 2005   Stabilized     1       42,138       0.4 %     42,138       100.0 %     58.0 %
36  
Pacific Center Boulevard
  August 24, 2007   Stabilized     2       66,745       0.6 %     66,745       100.0 %     100.0 %
37  
Road to the Cure
  December 14, 2006   Lease Up     1       67,998       0.6 %     54,104       79.6 %     79.6 %
38  
San Diego Science Center
  October 21, 2004   Lease Up     1       105,364       0.9 %     79,791       75.7 %     76.1 %
39  
10240 Science Center Drive
  September 23, 2010   Stabilized     1       49,347       0.4 %     49,347       100.0 %     100.0 %
40  
10255 Science Center Drive
  September 24, 2004   Stabilized     1       53,740       0.5 %     53,740       100.0 %     100.0 %
41  
Sorrento Valley Boulevard
  December 7, 2006   Stabilized     1       54,924       0.5 %     54,924       100.0 %     100.0 %
42  
11388 Sorrento Valley Road
  September 10, 2010   Stabilized     1       35,940       0.3 %     35,940       100.0 %     100.0 %
43  
Sorrento Plaza
  December 18, 2010   Stabilized     2       31,184       0.3 %     31,184       100.0 %     n/a  
44  
Sorrento West
  October 15, 2010   Stabilized     8       163,799       1.5 %     149,164       91.1 %     n/a  

22


 

(BIOMED REALTY TRUST,INC.LOGO)
PROPERTY LISTING — CONSOLIDATED PORTFOLIO
DECEMBER 31, 2010
                                                             
                        Rentable     Percent of     Leased        
            Property           Square     Rentable     Square     Percent Leased  
    Property   Acquisition Date   Status (1)   Buildings     Feet     Sq Ft     Feet     12/31/10     9/30/10  
   
San Diego (Continued)
                                                       
45  
Torreyana Road
  March 22, 2007   Stabilized     1       81,204       0.7 %     81,204       100.0 %     100.0 %
46  
9865 Towne Centre Drive
  August 12, 2004   Stabilized     2       94,866       0.8 %     94,866       100.0 %     100.0 %
47  
9885 Towne Centre Drive
  August 12, 2004   Stabilized     2       104,870       0.9 %     104,870       100.0 %     100.0 %
48  
Waples Street
  March 1, 2005   Stabilized     1       50,055       0.4 %     50,055       100.0 %     100.0 %
   
 
                                           
   
Total San Diego
            36       1,808,678       15.9 %     1,640,958       90.7 %     89.1 %
   
 
                                           
   
 
                                                       
   
Maryland
                                                       
49  
Beckley Street
  December 17, 2004   Stabilized     1       77,225       0.7 %     77,225       100.0 %     100.0 %
50  
9911 Belward Campus Drive
  May 24, 2006   Stabilized     1       289,912       2.6 %     289,912       100.0 %     100.0 %
51  
9920 Belward Campus Drive
  May 8, 2007   Stabilized     1       51,181       0.5 %     51,181       100.0 %     100.0 %
52  
Medical Center Drive
  May 3, 2010   Stabilized     5       217,983       1.9 %     217,983       100.0 %     100.0 %
53  
Shady Grove Road
  May 24, 2006   Stabilized     4       635,058       5.7 %     635,058       100.0 %     100.0 %
54  
Tributary Street
  December 17, 2004   Stabilized     1       91,592       0.8 %     91,592       100.0 %     100.0 %
55  
50 West Watkins Mill Road
  May 7, 2010   Stabilized     1       57,410       0.5 %     57,410       100.0 %     100.0 %
56  
55 / 65 West Watkins Mill Road
  February 23, 2010   Stabilized     2       82,405       0.7 %     82,405       100.0 %     100.0 %
   
 
                                           
   
Total Maryland
            16       1,502,766       13.4 %     1,502,766       100.0 %     100.0 %
   
 
                                           
   
 
                                                       
   
New York / New Jersey
                                                       
57  
Graphics Drive
  March 17, 2005   Lease Up     1       72,300       0.6 %     64,960       89.8 %     89.8 %
58  
Landmark at Eastview
  August 12, 2004   Lease Up     5       743,550       6.6 %     634,562       85.3 %     84.2 %
59  
Landmark at Eastview II
  August 12, 2004   Stabilized     3       360,520       3.2 %     360,520       100.0 %     100.0 %
60  
One Research Way
  May 31, 2006   Lease Up     1       49,421       0.4 %                  
   
 
                                           
   
Total New York / New Jersey
            10       1,225,791       10.8 %     1,060,042       86.5 %     85.8 %
   
 
                                           
   
 
                                                       
   
Pennsylvania
                                                       
61  
Eisenhower Road
  August 13, 2004   Lease Up     1       27,750       0.2 %     16,565       59.7 %     59.7 %
62  
George Patterson Boulevard
  October 28, 2005   Stabilized     1       71,500       0.6 %     71,500       100.0 %     100.0 %
63  
King of Prussia
  August 11, 2004   Lease Up     5       427,109       3.8 %     374,387       87.7 %     87.7 %
64  
Phoenixville Pike
  May 5, 2005   Stabilized     1       104,400       0.9 %     99,878       95.7 %     95.7 %
65  
Spring Mill Drive
  July 20, 2006   Stabilized     1       76,561       0.7 %     76,561       100.0 %     100.0 %
66  
900 Uniqema Boulevard
  January 13, 2006   Stabilized     1       11,293       0.1 %     11,293       100.0 %     100.0 %
67  
1000 Uniqema Boulevard
  September 30, 2005   Stabilized     1       59,821       0.5 %     59,821       100.0 %     100.0 %
   
 
                                           
   
Total Pennsylvania
            11       778,434       6.8 %     710,005       91.2 %     91.2 %
   
 
                                           
   
 
                                                       
   
Seattle
                                                       
68  
Elliott Avenue
  August 24, 2004   Lease Up     1       154,341       1.4 %                  
69  
500 Fairview Avenue
  January 28, 2008   Stabilized     1       22,213       0.2 %     22,213       100.0 %     100.0 %
70  
530 Fairview Avenue
  January 12, 2006   Lease Up     1       96,188       0.9 %     64,295       66.8 %     65.6 %
71  
Monte Villa Parkway
  August 17, 2004   Stabilized     1       51,000       0.5 %     51,000       100.0 %     100.0 %
72  
217th Place
  November 21, 2006   Lease Up     1       67,799       0.6 %     42,628       62.9 %     62.9 %
   
 
                                           
   
Total Seattle
            5       391,541       3.6 %     180,136       46.0 %     45.7 %
   
 
                                           
   
 
                                                       
   
University Related — Other
                                                       
73  
Lucent Drive
  May 31, 2005   Stabilized     1       21,500       0.2 %     21,500       100.0 %     100.0 %
74  
Paramount Parkway
  July 20, 2010   Stabilized     1       61,603       0.5 %     61,603       100.0 %     100.0 %
75  
Patriot Drive
  December 17, 2010   Lease Up     1       48,394       0.4 %     39,691       82.0 %     n/a  
76  
Trade Centre Avenue
  August 9, 2006   Stabilized     2       78,023       0.7 %     78,023       100.0 %     100.0 %
77  
Walnut Street
  July 7, 2006   Stabilized     4       149,984       1.3 %     149,984       100.0 %     100.0 %
78  
Weston Parkway
  December 17, 2010   Stabilized     1       30,589       0.3 %     30,589       100.0 %     n/a  
   
 
                                           
   
Total University Related — Other
            10       390,093       3.4 %     381,390       97.8 %     100.0 %
   
 
                                           
   
 
                                                       
   
Total / weighted average
            140       11,234,491       100.0 %     8,885,055       79.1 %     77.7 %
   
 
                                           
 
(1)   For a definition of Property Status, see page 34.
 
(2)   The Company owns 87.5% of the limited liability company that owns the Ardenwood Venture property. -

23


 

(BIOMED REALTY TRUST,INC.LOGO)
DEVELOPMENT / REDEVELOPMENT / PRE-DEVELOPMENT / DEVELOPMENT POTENTIAL
DECEMBER 31, 2010

(Dollars in thousands)
                                                     
                                        Estimated     Estimated  
        Rentable     Percent     Percent     Investment     Total     In-Service  
Property   Market   Square Feet     Leased     In Service     to Date (1)     Investment (2)     Date (3)  
DEVELOPMENT:  
 
                                               
Gazelle Court  
San Diego
    176,000       100.0 %         $ 32,400     $ 77,500       Q1 2012  
REDEVELOPMENT:  
 
                                               
N/A  
N/A
                                   
   
 
                                     
Total / weighted average  
 
    176,000       100.0 %         $ 32,400     $ 77,500          
   
 
                                     
                                                     
                                        Estimated     Estimated  
        Rentable     Percent     Percent     Investment     Total     In-Service  
Property   Market   Square Feet     Leased     In Service     to Date (1)     Investment (2)     Date (3)  
PRE-DEVELOPMENT:
                                                   
Eccles Avenue(4)
  San Francisco     152,145                 $ 25,000     TBD   TBD
DEVELOPMENT POTENTIAL:
         
    Estimated  
    Developable  
Market   Square Feet  
Boston
    50,000  
San Francisco
    1,454,000  
San Diego
    103,000  
Maryland
    529,000  
New York / New Jersey
    326,000  
Pennsylvania
    50,000  
Seattle
    114,000  
 
     
Total
    2,626,000  
 
     
 
(1)   Consists of amounts paid through period end and excludes any amounts accrued.
 
(2)   Excludes costs associated with speculative leasing.
 
(3)   Management’s estimate of the time in which construction is substantially completed. A project is considered substantially complete and held available for occupancy upon the completion of tenant improvements, but no later than one year from cessation of major construction activity.
 
(4)   Management is currently engaged in entitlement activities that it estimates could increase the rentable square footage of this property to approximately 260,000 square feet. The net new square feet is captured in development potential.

24


 

(BIOMED REALTY TRUST,INC.LOGO)
PROPERTY LISTING — UNCONSOLIDATED PARTNERSHIPS
DECEMBER 31, 2010

(Dollars in thousands)
                                                                 
                                Rentable     Leased              
                Property             Square     Square     Percent Leased      
    Property   Acquisition Date     Status (1)     Buildings     Feet     Feet     12/31/10     9/30/10   Market  
   
McKellar Court
                                                           
1  
McKellar Court
  September 30, 2004   Stabilized     1       72,863       72,863       100.0 %   100.0%   San Diego
   
 
                                                           
   
PREI
                                                           
2  
320 Bent Street
  April 4, 2007   Lease Up     1       184,405       145,304       78.8 %   100.0%   Boston
3  
301 Binney Street
  April 4, 2007   Lease Up     1       417,290       243,329       58.3 %   58.3%   Boston
4  
301 Binney Garage
  April 4, 2007   Lease Up     1     503 Stalls     n/a       n/a     n/a   Boston
5  
650 E. Kendall Street (Kendall B)
  April 4, 2007   Lease Up     1       280,000                   Boston
6  
350 E. Kendall Street Garage (Kendall F)
  April 4, 2007   Stabilized     1     1,409 Stalls     n/a       n/a     n/a   Boston
7  
Kendall Crossing Apartments
  April 4, 2007   Stabilized     1     37 Apts.     n/a       n/a     n/a   Boston
                         
    McKellar              
    Court (2)     PREI     Total  
Total assets
  $ 14,715     $ 652,344     $ 667,059  
Total debt (3)
    10,280       405,653       415,933  
Current annualized base rent
    1,845       23,532       25,377  
BioMed’s net investment in unconsolidated partnerships
  $ 12,520     $ 44,745     $ 57,265  
BioMed’s pro rata share of debt
          81,131       81,131  
BioMed ownership percentage
    22 %     20 %     20 %
 
(1)   For a definition of Property Status, see page 34.
 
(2)   The Company owns a general partnership interest in the limited partnership that owns this property, which entitles it to 75% of the gains upon a sale of the property and 22% of the operating cash flows.
 
(3)   McKellar Court’s debt is payable to BioMed Realty, L.P. and is included in investments in unconsolidated partnerships on the Company’s consolidated balance sheet.

25


 

(BIOMED REALTY TRUST INC. LOGO)
LEASE EXPIRATIONS
DECEMBER 31, 2010

 
Weighted average remaining lease term is 8.3 years for the consolidated portfolio and 8.2 years for the total portfolio
                                                                 
                    Current (1)     Expiration (2)  
                                    Annualized                     Annualized  
            Percent of             Percent of     Base Rent             Percent of     Base Rent  
    Leased     Leased     Annualized     Annualized     per Leased     Annualized     Annualized     per Leased  
Expiration   Square Feet     Square Feet     Base Rent     Base Rent     Square Feet     Base Rent     Base Rent     Square Feet  
                    (in thousands)                     (in thousands)                  
Month-to-month
    44,154       0.5 %   $ 682       0.2 %   $ 15.45     $ 682       0.2 %   $ 15.45  
First quarter 2011
    53,137       0.6 %     1,343       0.4 %     25.27       1,364       0.3 %     25.67  
Second quarter 2011
    172,982       1.9 %     3,327       0.9 %     19.23       3,327       0.8 %     19.23  
Third quarter 2011
    83,407       0.9 %     2,895       0.8 %     34.71       2,895       0.7 %     34.71  
Fourth quarter 2011
    38,961       0.4 %     691       0.2 %     17.74       691       0.2 %     17.74  
 
                                               
2011
    348,487       3.8 %     8,256       2.3 %     23.69       8,277       2.0 %     23.75  
2012
    629,170       6.7 %     22,830       6.4 %     36.29       23,453       5.6 %     37.28  
2013
    646,852       6.9 %     16,223       4.6 %     25.08       17,685       4.2 %     27.34  
2014
    797,021       8.5 %     22,368       6.3 %     28.06       24,299       5.8 %     30.49  
2015
    330,103       3.5 %     9,745       2.7 %     29.52       10,518       2.5 %     31.86  
2016
    1,167,445       12.5 %     45,407       12.8 %     38.89       52,922       12.5 %     45.33  
2017
    118,045       1.3 %     3,587       1.0 %     30.39       4,325       1.0 %     36.64  
2018
    1,117,326       12.0 %     50,537       14.3 %     45.23       56,683       13.4 %     50.73  
2019
    270,150       2.9 %     7,692       2.2 %     28.47       9,661       2.3 %     35.76  
2020
    537,250       5.7 %     19,297       5.4 %     35.92       18,785       4.5 %     34.97  
Thereafter
    3,340,548       35.7 %     147,782       41.8 %     44.24       194,812       46.0 %     58.32  
 
                                               
 
                                                               
Total / weighted average
    9,346,551       100.0 %   $ 354,406       100.0 %   $ 37.92     $ 422,102       100.0 %   $ 45.16  
 
                                               
 
(1)   Current annualized base rent is the monthly contractual rent as of the current quarter ended, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.
 
(2)   Annualized base rent at expiration is the montly contractual rent as of the date of expiration of the applicable lease (not including any extension option(s)), multiplied by 12 months.

26


 

(BIOMED REALTY TRUST INC. LOGO)
EXPIRATIONS BY MARKET
DECEMBER 31, 2010

 
                                                                         
    Leased Square Feet  
Expiration   Boston     San Francisco     San Diego     Maryland     NY/NJ     Pennsylvania     Seattle     University/Other     Total  
Month-to-month
                5,808             38,346                         44,154  
2011
    37,388             103,701       113,784       10,796       82,818                   348,487  
2012
    21,705       313,153       203,176             55,546       13,377       22,213             629,170  
2013
    12,972       213,826       226,248             136,594       44,318       3,962       8,932       646,852  
2014
    28,019       55,098       101,084       121,414             396,776       42,541       52,089       797,021  
2015
          57,950       206,641                   34,753             30,759       330,103  
2016
    618,161       186,061                   10,555       31,166       31,892       289,610       1,167,445  
2017
                21,470       51,181       45,394                         118,045  
2018
    807,347       121,590       145,761                         42,628             1,117,326  
2019
    2,676       61,757             168,817                   36,900             270,150  
2020
    111,144       50,000       72,863       122,600       180,643                         537,250  
Thereafter
    562,445       537,099       627,069       924,970       582,168       106,797                   3,340,548  
 
                                                     
 
                                                                       
Total
    2,201,857       1,596,534       1,713,821       1,502,766       1,060,042       710,005       180,136       381,390       9,346,551  
 
                                                     

27


 

(BIOMED REALTY TRUST.INC LOGO)
10 LARGEST TENANTS
DECEMBER 31, 2010

 
BioMed’s properties were leased to 160 tenants.
                                                         
                                    Annualized     Percent of        
                                    Base Rent     Annualized        
            Leased             Annualized     per Leased     Base Rent        
            Square     Percent of     Base Rent     Sq Ft     Current     Lease  
        Tenant   Feet     Leased Sq Ft     Current (1)     Current     Total Portfolio     Expiration  
                            (In thousands)                          
  1    
Human Genome Sciences, Inc.
    924,970       9.9 %   $ 42,756     $ 46.22       12.1 %   June 2026
  2    
Vertex Pharmaceuticals Incorporated (2)
    685,286       7.3 %     31,167       45.48       8.8 %   Multiple
  3    
Elan Pharmaceuticals, Inc. (3)
    419,628       4.5 %     26,121       62.25       7.4 %   Multiple
  4    
Beth Israel Deaconess Medical Center, Inc.
    362,364       3.9 %     25,543       70.49       7.2 %   July 2023
  5    
Regeneron Pharmaceuticals, Inc. (4)
    564,547       6.0 %     22,818       40.42       6.4 %   Multiple
  6    
Genzyme Corporation
    343,000       3.7 %     15,464       45.08       4.4 %   August 2018
  7    
Merck & Co., Inc. (5)
    214,946       2.3 %     10,003       46.54       2.8 %   Multiple
  8    
Children’s Hospital Corporation
    150,215       1.6 %     9,151       60.92       2.6 %   May 2023
  9    
Ironwood Pharmaceuticals, Inc. (6)
    163,646       1.8 %     8,787       53.70       2.5 %   February 2016
  10    
Centocor Ortho Biotech, Inc. (Johnson & Johnson)
    374,387       4.0 %     8,490       22.68       2.4 %   April 2014
     
 
                                   
       
 
                                               
       
Total / weighted average (7)
    4,202,989       45.0 %   $ 200,300     $ 47.66       56.6 %        
     
 
                                   
 
(1)   Based on current annualized base rent. Current annualized base rent is the monthly contractual rent as of the current quarter ended, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.
 
(2)   20,608 square feet expires May 2012, 81,204 square feet expires October 2013, 292,758 square feet expires January 2016, and 290,716 square feet expires May 2018.
 
(3)   5,198 square feet expires January 2011, 138,963 square feet expires December 2012, 15,482 square feet expires January 2013, 55,098 square feet expires December 2014, 115,888 square feet expires April 2024, and 88,999 square feet expires February 2025.
 
(4)   16,725 square feet expires March 2011, 6,568 square feet expires August 2011, and 541,254 square feet expires July 2024.
 
(5)   The Company owns 20% of the limited liability company that owns 320 Bent, a property at which this tenant leases 145,304 square feet. This tenant also guarantees rent on 39,053 square feet leased at Landmark at Eastview and 30,589 square feet leased at Weston Parkway. 39,053 square feet expires July 2012, 30,589 square feet expires January 2014 and 145,304 square feet expires September 2016.
 
(6)   The Company owns 20% of the limited liability company that owns 301 Binney, at which this tenant leases 163,646 square feet.
 
(7)    Without regard to any early lease terminations and/or renewal options.

28


 

(BIOMED REALTY TRUST INC LOGO)
SAME PROPERTY ANALYSIS
DECEMBER 31, 2010

(Dollars in thousands)
                         
    Quarter Ended  
    12/31/10     12/31/09     Percent Change  
Total Same Property Portfolio (1)
                       
Number of properties
    66       66          
Rentable square feet
    9,922,588       9,922,588          
Percent of total portfolio
    81.4 %     94.3 %        
Percent leased
    78.1 %     78.7 %        
                         
Revenues:
                       
Rental
  $ 75,838     $ 71,569       6.0 %
Tenant recoveries
    25,904       23,276       11.3 %
 
                 
Total revenues
    101,742       94,845       7.3 %
 
                 
                         
Expenses:
                       
Rental operations
    21,795       19,140       13.9 %
Real estate taxes
    9,973       9,709       2.7 %
 
                 
Total expenses
    31,768       28,849       10.1 %
 
                 
Same property net operating income (2)
  $ 69,974     $ 65,996       6.0 %
 
                 
Less straight line rents, fair-value lease revenue, lease incentive revenue, and bad debt expense
    (2,154 )     (6,041 )     (64.3 %)
 
                 
Same property net operating income — cash basis (2) (3)
  $ 67,820     $ 59,955       13.1 %
 
                 
                         
Rental revenue — cash basis (3)
  $ 71,870     $ 63,846       12.6 %
 
                 
 
(1)   The same property portfolio includes properties that were stabilized or in lease up throughout the full quarter in both the current year and the prior year.
 
(2)   For a definition and discussion of net operating income, see page 33. For a quantitative reconciliation of net operating income to net income in accordance with GAAP, see page 14.
 
(3)   Represents rents on a “cash-on-cash” basis.

29


 

(BIOMED REALTY TRUST INC LOGO)
ACQUISITIONS
DECEMBER 31, 2010
                         
            Rentable        
    Number of     Square        
Acquisitions since August 11, 2004:   Properties     Feet (1)     Investment  
                    (In thousands)  
2004 acquisitions
    17       2,626,875     $ 533,434  
2005 acquisitions
    23       2,121,421       715,159  
2006 acquisitions
    16       3,099,826       1,309,600  
2007 acquisitions (2)
    14       1,102,822       653,800  
2008 acquisitions
    1       22,213       4,000  
2009 acquisitions
                 
2010 acquisitions
    16       1,503,975       608,738  
 
                 
Total acquisitions since August 11, 2004
    87       10,477,132     $ 3,824,731  
 
                 
                                 
Acquisitions detail for 2010:           Rentable             Percent  
            Square             Leased at  
Property   Market   Closing Date   Feet (1)     Investment     Acquisition  
                    (In thousands)          
First Quarter 2010
                               
55 / 65 West Watkins Mill Road
  Maryland   February 23, 2010     82,405     $ 14,385       100.0 %
Gazelle Court (3)
  San Diego   March 30, 2010           11,623       100.0 %
 
                         
First quarter total
            82,405     $ 26,008       100.0 %
 
                         
 
                               
Second Quarter 2010
                               
Medical Center Drive
  Maryland   May 3, 2010     217,983     $ 53,000       100.0 %
50 West Watkins Mill Road
  Maryland   May 7, 2010     57,410       14,200       100.0 %
 
                         
Second quarter total
            275,393     $ 67,200       100.0 %
 
                         
 
                               
Third Quarter 2010
                               
4775 / 4785 Executive Drive
  San Diego   July 15, 2010     62,896     $ 27,280        
Paramount Parkway
  University Related - Other   July 20, 2010     61,603       17,549       100.0 %
11388 Sorrento Valley Road
  San Diego   September 10, 2010     35,940       12,420       100.0 %
4570 Executive Drive
  San Diego   September 17, 2010     125,219       63,500       100.0 %
10240 Science Center Drive
  San Diego   September 23, 2010     49,347       17,750       100.0 %
 
                         
Third quarter total
            335,005     $ 138,499       81.2 %
 
                         
Fourth Quarter 2010
                               
Sorrento West
  San Diego   October 15, 2010     163,799     $ 29,390       94.3 %
Sorrento Plaza
  San Diego   October 18, 2010     31,184       9,875       100.0 %
Science Center at Oyster Point
  San Francisco   October 26, 2010     204,887       133,250       100.0 %
Gateway Business Park
  San Francisco   October 26, 2010     284,013       164,946       100.0 %
Patriot Drive
  University Related - Other   December 17, 2010     48,394       8,570       82.0 %
Weston Parkway
  University Related - Other   December 17, 2010     30,589       6,100       100.0 %
3525 John Hopkins Court
  San Diego   December 28, 2010     48,306       24,900       100.0 %
 
                         
Fourth quarter total
            811,172     $ 377,031       97.8 %
 
                         
Total 2010 acquisitions
            1,503,975     $ 608,738       94.6 %
 
                         
 
(1)   Rentable square feet at the time of acquisition.
 
(2)   Includes an investment of approximately $506.7 million in properties owned through the Company’s joint venture with PREI, of which the Company’s investment was $18.5 million.
 
(3)   The total estimated cost for this property is $77.5 million upon the completion of construction of an approximately 176,000 square foot building.

30


 

(BIOMED REALTY TRUST INC LOGO)
LEASING ACTIVITY (1)
DECEMBER 31, 2010
                 
            Current  
    Leased     Annualized  
    Square     Base Rent per  
    Feet     Leased Sq Ft  
Leased Square Feet as of September 30, 2010
    8,596,972          
Acquisitions
    793,107     $ 44.00  
Expirations
    (374,911 )     20.36  
Pre-leased delivery
    7,226       21.00  
Renewals, amendments, and extensions
    167,310       18.11  
New leases
    156,847       19.57  
 
             
Leased Square Feet as of December 31, 2010
    9,346,551          
 
             
 
Pre-leased Square Feet as of September 30, 2010
    24,295          
Pre-leased new leases
    5,029       10.80  
Pre-leased delivery
    (7,226 )     21.00  
 
             
Pre-leased Square Feet as of December 31, 2010
    22,098          
 
             
 
Gross Leasing Activity — Fourth Quarter 2010
    329,186     $ 18.75  
 
             
 
(1)   Leasing activity for leases signed during the periods presented, which may be different than the period of actual occupancy.

31


 

(BIOMED REALTY TRUST INC LOGO)
TENANT IMPROVEMENTS AND LEASING COMMISSIONS
DECEMBER 31, 2010
                                         
    Three Months Ended  
    12/31/10     9/30/10     6/30/10     3/31/10     12/31/09  
Renewals, Amendments, and Extensions (1)
                                       
Number of renewals
    5       4       3       5       6  
Square feet
    167,310       141,310       33,468       70,526       262,714  
Tenant improvement costs per square foot (2)
  $ 3.07     $     $ 29.88     $ 1.66     $ 16.79  
Leasing commission costs per square foot (2)
    5.06       6.36       3.33       3.78       2.17  
 
                             
Total tenant improvement and leasing commission costs psf
  $ 8.13     $ 6.36     $ 33.21     $ 5.44     $ 18.96  
 
                             
 
New Leases (3)
                                       
Number of leases
    8       10       9       8       11  
Square feet
    161,876       90,351       126,407       84,581       325,988  
Tenant improvement costs per square foot (2)
  $ 88.54     $ 43.06     $ 64.22     $ 44.09     $ 99.77  
Leasing commission costs per square foot (2)
    13.05       6.76       8.82       8.91       10.62  
 
                             
Total tenant improvement and leasing commission costs psf
  $ 101.59     $ 49.82     $ 73.03     $ 53.00     $ 110.39  
 
                             
 
Total
                                       
Number of renewals/leases
    13       14       12       13       17  
Square feet
    329,186       231,661       159,875       155,107       588,702  
Tenant improvement costs per square foot (2)
  $ 45.10     $ 16.79     $ 57.03     $ 24.80     $ 62.74  
Leasing commission costs per square foot (2)
    8.99       6.52       7.67       6.57       6.85  
 
                             
Total tenant improvement and leasing commission costs psf
  $ 54.09     $ 23.31     $ 64.70     $ 31.37     $ 69.59  
 
                             
 
(1)   Does not include retained tenants that have relocated to new space or expanded into new space.
 
(2)   Assumes all tenant improvements and leasing commissions are paid in the calendar year in which the lease commences, which may be different than the year in which they are actually paid.
 
(3)   Includes pre-leasing activity and retained tenants that have relocated to new space or expanded into new space within the Company’s portfolio.

32


 

(BIOMED REALTY TRUST INC LOGO)
NON-GAAP FINANCIAL MEASURE DEFINITIONS
DECEMBER 31, 2010
This document includes certain non-GAAP financial measures that management believes are helpful in understanding our business, as further described below. Our definition and calculation of non-GAAP financial measures may differ from those of other REITs, and therefore, may not be comparable. The non-GAAP measures should not be considered an alternative to net income as an indicator of our performance and should be considered only a supplement to cash flows from operating, investing or financing activities as a measure of liquidity, computed in accordance with GAAP.
Funds from Operations (FFO)
We present funds from operations, or FFO, because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides a performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management’s discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.
Adjusted Funds from Operations (AFFO)
We present adjusted funds from operations, or AFFO, as a supplemental operating measure because, when compared year over year, it assesses our ability to fund dividend and distribution requirements from our operating activities. We also believe that, as a widely recognized measure of the operations of REITs, AFFO will be used by investors as a basis to assess our ability to fund dividend payments in comparison to other REITs. We calculate AFFO by adding to FFO: (a) amounts received pursuant to master lease agreements on certain properties, which are not included in rental income for GAAP purposes, (b) non-cash revenues and expenses, (c) recurring capital expenditures and tenant improvements, and (d) leasing commissions. Other equity REITs may not calculate AFFO in a consistent manner. Accordingly, our AFFO may not be comparable to other equity REITs’ AFFO. AFFO should be considered only as a supplement to net income computed in accordance with GAAP as a measure of our operations.
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA
EBITDA is defined as earnings before interest, taxes, depreciation and amortization. We calculate adjusted EBITDA by adding to EBITDA: (a) noncontrolling interests in our operating partnership and (b) dividends payable on our series A preferred stock. Management uses EBITDA and adjusted EBITDA as indicators of our ability to incur and service debt. In addition, we consider EBITDA and adjusted EBITDA to be appropriate supplemental measures of our performance because they eliminate depreciation and interest, which permits investors to view income from operations without the impact of non-cash depreciation or the cost of debt. However, because EBITDA and adjusted EBITDA are calculated before recurring cash charges including interest expense and taxes, and are not adjusted for capital expenditures or other recurring cash requirements of our business, their utility is limited.
Coverage Ratios
We present interest and fixed charge ratios as supplemental liquidity measures. Management uses these ratios as indicators of our financial flexibility to service current interest expense and debt amortization from current cash net operating income. In addition, we believe that these coverage ratios represent common metrics used by securities analysts, investors and other interested parties to evaluate our ability to service fixed cash payments. However, because these ratios are derived from adjusted EBITDA, their utility is limited by the same factors that limit the usefulness of adjusted EBITDA as a liquidity measure.
Net Operating Income (NOI)
We use net operating income, or NOI, as a performance measure and believe NOI provides useful information to investors regarding our financial condition and results of operations because it reflects only those income and expense items that are incurred at the property level. We compute NOI by adding or subtracting certain items from net income, noncontrolling interest in the operating partnership, gains/losses from investment in unconsolidated partnerships, interest expense, interest income, depreciation and amortization, and general and administrative expenses. NOI presented by us may not be comparable to NOI reported by other REITs that define NOI differently. NOI should not be considered as an alternative to net income as an indication of our performance or to cash flows as a measure of liquidity or ability to make distributions.

33


 

(BIOMED REALTY TRUST INC LOGO)
PROPERTY DEFINITIONS
DECEMBER 31, 2010
Property Status

Stabilized
Represents operating properties that are more than 90% leased
Lease up
Represents operating properties that are less than 90% leased
Redevelopment
Represents properties that we are currently preparing for their intended use, and accordingly are capitalizing interest and other costs as of the end of the quarter
Development
Represents properties that we are currently developing through ground up construction
Development Potential, or Land
Represents estimates of the additional rentable square footage that we could put into service if management made the strategic election to pursue additional development

34